IP Verse

Capsule Formulations - EP3886820

The patent EP3886820 was granted to Chemocentryx on May 17, 2023. The application was originally filed on Nov 27, 2019 under application number EP19889873A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3886820

CHEMOCENTRYX
Application Number
EP19889873A
Filing Date
Nov 27, 2019
Status
Granted And Under Opposition
Mar 10, 2023
Grant Date
May 17, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LEK PHARMACEUTICALS DDJan 12, 2024ELKINGTON AND FIFEADMISSIBLE
HAMM & WITTKOPPJan 11, 2024WITTKOPPADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2007298099
INTERNATIONAL-SEARCH-REPORTUS2010311753
INTERNATIONAL-SEARCH-REPORTUS2017246186
INTERNATIONAL-SEARCH-REPORTUS2018179160
INTERNATIONAL-SEARCH-REPORTUS2018280530
OPPOSITIONEP2381778
OPPOSITIONUS2007298099
OPPOSITIONUS2010311753
OPPOSITIONUS2011086844
OPPOSITIONUS2011312973
OPPOSITIONUS2016346207
OPPOSITIONUS2017246186
OPPOSITIONUS2018179160
OPPOSITIONUS2018280530
OPPOSITIONUS8632763
OPPOSITIONWO2011163640
OPPOSITIONWO2017123716
OPPOSITIONWO2019089534

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Male and Female Subjects", ChemoCentryx, Inc.; Protocol CL001_168, (20091005), XP093190832-
OPPOSITION- Anonymous, "Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE); NCT03301467", ClinicalTrials.gov; NCT03301467, (20180914), ClinicalTrials.gov; NCT03301467, URL: https://clinicaltrials.gov/study/NCT03301467?term=NCT03301467&rank=1&tab=history&a=10#version-content-panel, XP093199914-
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 76", WHO DRUG INFORMATION, GENEVA, CH, CH , (20160101), vol. 30, no. 3, ISSN 1010-9609, pages 477 - 544, XP093154418-
OPPOSITION- Anonymous, "NDA Multi-disciplinary Review and Evaluation NDA 214487 Avacopan, ANCA-associated vasculitis (GPA and MPA)", MULTI-DISCIPLINE REVIEW, CENTER FOR DRUG EVALUATION AND RESEARCH, (20181012), pages 1 - 751, MULTI-DISCIPLINE REVIEW, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000MultidisciplineR.pdf, XP093154439-
OPPOSITION- Anonymous, "New method: More pharmaceuticals could benefit from the stabilizing influence of fluorine atoms", PHYS.ORG, (20121005), XP093199909-
OPPOSITION- Chemocentryx, Inc., "Protocol CL003_168 Amendment 4.0; A Randomized, Double-Blind, Placebo-Controlled, DoseAssessment Phase 2 Study to Evalhate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis ", Protocol Amendment 4.0, (20160219), pages 1 - 101, Protocol Amendment 4.0, URL: https://classic.clinicaltrials.gov/ProvidedDocs/67/NCT03301467/Prot_000.pdf, XP093154489-
OPPOSITION- Chemocentryx, "NCT02222155 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis", ClinicalTrials.gov, NLM, (20161115), pages 1 - 11, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02222155?tab=history&a=10, XP093154287-
OPPOSITION- Dave A. Miller, James W. McGinity, and Robert O. Williams III, "Chapter 13: Solid Dispersion Technologies", Dave A. Miller, James W. McGinity, and Robert O. Williams III, Robert O. Williams III, David R. Taft, Jason T. McConville, Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, US, New York [u.a.] : Informa Healthcare, (20080101), pages 451 - 491, ISBN 978-1-4200-4387-7, XP009556675-
OPPOSITION- Hendrik Hardung et al., "Combining HME & Solubilization: Soluplus® -The Solid Solution", Drug Delivery Technology, (2010), vol. 10, page 3, XP009155307-
OPPOSITION- Ich Expert Working Group, "ICH HARMONISED TRIPARTITE GUIDELINE - STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS Q1A (R2)", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20030206), pages 1 - 18, XP055268662-
OPPOSITION- Michael E. Aulton, "Chapter 2: Dissolution and solubility: Part 1: Scientific principles of dosage form design", Aulton's Pharmaceutics, Edinburgh, Elsevier, (20180101), pages 18 - 36, ISBN 978-0-7020-7003-7, XP093154484-
OPPOSITION- O G Bhusnure, "Solid dispersions: An evergreen solubility enhancement technique for hydrophobic drugs", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, (20140101), vol. 4, no. 4, ISSN 2231-2781, pages 906 - 918, XP093154266-
OPPOSITION- Pardeep K. Gupta, "Chapter 13: Solutions and Phase Equilibria", Pardeep K. Gupta, Linda Felton, Remington, Essentials of Pharmaceutics, GB, Pharmaceutical Press , (20120101), pages 219 - 239, ISBN 978-0-85711-105-0, XP009553652-
OPPOSITION- Raymond C. Rowe, "Macrogol 15 Hydroxystearate", Raymond C. Rowe, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 391 - 392, ISBN 978-0-85369-792-3, XP093154384-
OPPOSITION- Raymond C. Rowe, Paul J. Sheskey, Marian E. Quinn, "Polyethylene Glycol", Raymond C. Rowe, Paul J. Sheskey, Marian E. Quinn, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 517 - 522, ISBN 978-0-85369-792-3, XP009553538-
OPPOSITION- Raymond C. Rowe, "Polyoxythylene Castor Oil Derivatives", Raymond C. Rowe, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 542 - 549, ISBN 978-0-85369-792-3, XP093154391-
OPPOSITION- Sophia Van Arnum, "Solubilizing the Insoluble: An analysis of the approaches and tools used to tackle the problem of poorly soluble drugs", Pharmaceutical Technology, ADVANSTAR COMMUNICATIONS,INC., US, US , (20101101), vol. 34, no. 11, ISSN 1543-2521, pages 50 - 56, XP093154262-
OPPOSITION- Who Drug, "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 76", WHO Drug Information, (20160101), vol. 30, no. 3, pages 477 - 481, XP093154325-
OPPOSITION- Peter A. Merkel, "2738: A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis", Arthritis & Rheumatology, John Wiley & Sons, Inc., US, US , (20180901), vol. 70, no. S9, doi:10.1002/art.40700, ISSN 2326-5191, pages 3068 - 3069, XP093154248
OPPOSITION- Tsume Yasuhiro; Mudie Deanna M.; Langguth Peter; Amidon Greg E.; Amidon Gordon L., "The Biopharmaceutics Classification System: Subclasses forin vivopredictive dissolution (IPD) methodology and IVIVC", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20140128), vol. 57, doi:10.1016/j.ejps.2014.01.009, ISSN 0928-0987, pages 152 - 163, XP028648885
OPPOSITION- Reginald-Opara Joy Nneji; Attama Anthony; Ofokansi Kenneth; Umeyor Chukwuebuka; Kenechukwu Frankline, "Molecular interaction between glimepiride and Soluplus®-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20151112), vol. 496, no. 2, doi:10.1016/j.ijpharm.2015.11.007, ISSN 0378-5173, pages 741 - 750, XP029344073
OPPOSITION- X Guo et al., "Calculation of hydrophile-lipophile balance for polyethoxylated surfactants by group contribution method", Journal of Colloid and Interface Science , (2006), vol. 298, doi:10.1016/j.jcis.2005.12.009, XP024909648
OPPOSITION- SERAJUDDIN, A. T. M., "SOLID DISPERSION OF POORLY WATER-SOUBLE DRUGS: EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS.", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (19991001), vol. 88., no. 10., doi:10.1021/js980403l, ISSN 0022-3549, pages 1058 - 1066., XP000851882
OPPOSITION- M. Jayne Lawrence, "Surfactant systems: their use in drug delivery", Chemical Society Reviews, Royal Society of Chemistry, UK, UK , (19941201), vol. 23, no. 6, doi:10.1039/cs9942300417, ISSN 0306-0012, page 417, XP093154422
OPPOSITION- David R.W. Jayne, "Avacopan for the Treatment of ANCA-Associated Vasculitis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20210218), vol. 384, no. 7, doi:10.1056/NEJMoa2023386, ISSN 0028-4793, pages 599 - 609, XP093154275
OPPOSITION- David R.W. Jayne, "Protocol: Avacopan for the Treatment of ANCA-Associated Vasculitis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20210218), vol. 384, no. 7, doi:10.1056/NEJMoa2023386, ISSN 0028-4793, pages 1 - 176, XP093154276
OPPOSITION- Shweta Gupta, Rajesh Kesarla, and Abdelwahab Omri, "Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.", ISRN PHARMACEUTICS 26 DEC 2013, (20131226), vol. 2013, doi:10.1155/2013/848043, ISSN 2090-6145, pages 1 - 16, XP002767351
OPPOSITION- Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel Johnson, Jay Powers, Juan Jaen, Israel Charo, Thomas J. Schall, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS ONE, vol. 11, no. 10, doi:10.1371/journal.pone.0164646, page e0164646, XP055602780
OPPOSITION- David R.W. Jayne, Annette N. Bruchfeld, Lorraine Harper, Matthias Schaier, Michael C. Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimír Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis", Journal of the American Society of Nephrology, WILLIAMS AND WILKINS, BALTIMORE, MD., US, US , (20170901), vol. 28, no. 9, doi:10.1681/ASN.2016111179, ISSN 1046-6673, pages 2756 - 2767, XP055602776
OPPOSITION- Shashank Soni, "PREPARATION AND IN VITRO CHARACTERIZATION OF ACETAMINOPHEN BY SOLID SOLUTION TECHNIQUE", Journal of Drug Delivery and Therapeutics, Vinita Nagar, (20120915), vol. 2, no. 5, doi:10.22270/jddt.v2i5.264, ISSN 2250-1177, pages 71 - 74, XP093154269
OPPOSITION- Anna Czajkowska-Kośnik, Et Al, "Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin", Molecules, vol. 20, no. 12, doi:10.3390/molecules201219745, pages 21010 - 21022, XP055397258
SEARCH[ ] - No further relevant documents disclosed-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents